Rogaratinib
- Generic Name
- Rogaratinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N6O3S
- CAS Number
- 1443530-05-9
- Unique Ingredient Identifier
- 98BSN6N516
- Background
Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
Rogaratinib/Atezolizumab in Cisplatin-Ineligible FGFR mRNA-Overexpressing Urothelial Cancer
Rogaratinib and atezolizumab combo active in cisplatin-ineligible urothelial cancer patients overexpressing FGFR mRNA. 43% objective responses, 65% disease control. Recommended phase II dose: rogaratinib 600 mg twice daily plus atezolizumab 1,200 mg. Median PFS: 7.5 months (600 mg) vs 2.1 months (800 mg). Median OS: 16.8 months (600 mg) vs 8.3 months (800 mg).
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA
Phase 1b study of rogaratinib (600 mg) plus atezolizumab (1200 mg) in 153 patients with advanced/metastatic urothelial carcinoma and FGFR3 mRNA overexpression shows a tolerable combination with a high objective response rate, indicating potential broad benefit for FGFR mRNA-positive patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath